- Home
- GMAB vs RXO Comparison
GMAB vs RXO Comparison
Compare GMAB & RXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GMAB
- RXO
- Stock Information
- Founded
- GMAB 1999
- RXO 2022
- Country
- GMAB Denmark
- RXO United States
- Employees
- GMAB N/A
- RXO N/A
- Industry
- GMAB Biotechnology: Pharmaceutical Preparations
- RXO
- Sector
- GMAB Health Care
- RXO
- Exchange
- GMAB Nasdaq
- RXO Nasdaq
- Market Cap
- GMAB 12.8B
- RXO 2.8B
- IPO Year
- GMAB N/A
- RXO N/A
- Fundamental
- Price
- GMAB $20.95
- RXO $15.54
- Analyst Decision
- GMAB Buy
- RXO Hold
- Analyst Count
- GMAB 9
- RXO 17
- Target Price
- GMAB $39.17
- RXO $20.80
- AVG Volume (30 Days)
- GMAB 1.5M
- RXO 1.8M
- Earning Date
- GMAB 05-08-2025
- RXO 05-07-2025
- Dividend Yield
- GMAB N/A
- RXO N/A
- EPS Growth
- GMAB 276.13
- RXO N/A
- EPS
- GMAB 18.36
- RXO N/A
- Revenue
- GMAB $3,230,902,140.00
- RXO $5,070,000,000.00
- Revenue This Year
- GMAB $17.69
- RXO $36.75
- Revenue Next Year
- GMAB $14.81
- RXO $7.54
- P/E Ratio
- GMAB $11.30
- RXO N/A
- Revenue Growth
- GMAB 25.21
- RXO 32.38
- 52 Week Low
- GMAB $17.24
- RXO $12.19
- 52 Week High
- GMAB $28.96
- RXO $32.82
- Technical
- Relative Strength Index (RSI)
- GMAB 55.72
- RXO 50.14
- Support Level
- GMAB $20.73
- RXO $15.16
- Resistance Level
- GMAB $21.42
- RXO $15.83
- Average True Range (ATR)
- GMAB 0.45
- RXO 0.60
- MACD
- GMAB 0.11
- RXO -0.00
- Stochastic Oscillator
- GMAB 81.62
- RXO 29.81
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
About RXO RXO Inc.
RXO Inc is a brokered transportation platform defined by cutting-edge technology and a nimble, asset-light business model, with the component being core truck brokerage business. Its operations also include three asset-light, brokered transportation services, all of which complement its truck brokerage business: managed transportation, last mile and freight forwarding. The company operates into one reportable segment. The operates within the transportation industry and in the same geography North America.